GLP1R and type 2 diabetes mellitus: In this study, we explore the impact of SGLT2i and GLP1-ra therapy on the risk for developing diabetic retinopathy and DMO, through a real-world study from a global federated database, including around two million people with type 2 diabetes receiving insulin treatment.